SynGenSys introduces expanded CHO.SET synthetic promoter library for enhanced biomanufacturing
CHO.SET® 2.0 library of synthetic promoters provide tuneable expression of transgenes whilst maximizing CHO cell productivity
19 Aug 2026
SynGenSys has introduced CHO.SET® 2.0, its expanded library of novel and patentable synthetic promoters is designed to improve protein production in CHO (Chinese Hamster Ovary) cells.
Since it was first introduced two years ago, the CHO.SET Library® has since been expanded and optimized, reflecting SynGenSys’ continued commitment to addressing critical biomanufacturing bottlenecks.
Current market vectors rely heavily on natural promoters such as CMV and SV40E, which have restricted transcriptional activity and are therefore insufficient for generating the high productivities required for modern commercial biotechnology applications.
Developed de novo using the Company’s proprietary transcriptional analysis and sequence engineering platform, CHO.SET® synthetic promoters combine advanced computational design with empirical validation to deliver a highly diverse promoter library applicable across a wide range of CHO expression systems and biomanufacturing requirements.
New supporting data demonstrate that CHO.SET® promoters outperform standard industry promoters, delivering enhanced transcriptional activity and improved protein production metrics. Selected vectors have been shown to achieve over 4x higher antibody productivity, with titers exceeding 2 g/L in a simple fed-batch flask model.
The CHO.SET® synthetic promoter pools also contain a higher proportion of high-expressing cells, increasing the likelihood of isolating top-performing clones. CHO.SET® supports more efficient and streamlined cell line development workflows, achieving high titers without the need for MSX, reducing process complexity and enabling faster recovery timelines and route to materials for toxicity studies.
Dr Andrew Racher, Co-CEO, SynGenSys, commented, said, “CHO cells are the pharmaceutical industry’s gold-standard cell factories, and CHO cell-specific synthetic promoters provide an elegant solution to overcoming key productivity limitations in the industry. We are excited to release this latest update and to continue providing solutions that address evolving biomanufacturing needs.”
Want the latest science news straight to your inbox? Become a SelectScience member for free today>>
Tags
Frequently asked questions
Show frequently asked questions
How does SynGenSys’ CHO.SET 2.0 synthetic promoter library improve protein production in CHO cells?
CHO.SET® 2.0 is an expanded library of novel, patentable synthetic promoters developed de novo using SynGenSys’ proprietary transcriptional analysis and sequence engineering platform. These CHO cell–specific promoters show enhanced transcriptional activity compared with natural promoters like CMV and SV40E, leading to improved protein production metrics and supporting higher productivities required for modern biomanufacturing.
What performance advantages do CHO.SET synthetic promoters offer over standard industry promoters such as CMV and SV40E?
New data show CHO.SET® promoters outperform standard industry promoters by delivering higher transcriptional activity and improved protein production. Selected vectors using CHO.SET® have achieved over 4x higher antibody productivity, with titers exceeding 2 g/L in a simple fed-batch flask model. The promoter pools also contain a higher proportion of high-expressing cells, increasing the chance of isolating top-performing CHO clones.
How does CHO.SET 2.0 support more efficient CHO cell line development and biomanufacturing workflows?
CHO.SET® synthetic promoter pools enrich for high-expressing CHO cells, streamlining cell line development and enabling high titers without the need for MSX. This reduces process complexity, supports faster recovery timelines, and accelerates the route to materials for toxicity studies. By addressing key productivity bottlenecks, CHO.SET® 2.0 helps biomanufacturers optimize CHO expression systems for commercial biotechnology applications.